Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Titan Pharmaceuticals stock | $2.45

Learn how to easily invest in Titan Pharmaceuticals stock.

Titan Pharmaceuticals, Inc
NASDAQ: TTNP - USD
BIOTECHNOLOGY
$2.28
-$0.05 (-2.15%)

Titan Pharmaceuticals, Inc is a biotechnology business based in the US. Titan Pharmaceuticals shares (TTNP) are listed on the NASDAQ and all prices are listed in US Dollars. Titan Pharmaceuticals employs 12 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Titan Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TTNP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Titan Pharmaceuticals stock price (NASDAQ: TTNP)

Use our graph to track the performance of TTNP stocks over time.

Titan Pharmaceuticals shares at a glance

Information last updated 2021-07-30.
Latest market close$2.45
52-week range$2.15 - $9.53
50-day moving average $2.45
200-day moving average $2.81
Wall St. target price$7.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.93

Buy Titan Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Titan Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Titan Pharmaceuticals price performance over time

Historical closes compared with the close of $2.45 from 2021-05-26

1 week (2021-07-20) N/A
1 month (2021-07-01) -4.67%
3 months (2021-04-30) -2.78%
6 months (2021-01-27) N/A
1 year (2020-07-27) N/A
2 years (2019-07-27) N/A
3 years (2018-07-27) N/A
5 years (2016-07-27) N/A

Titan Pharmaceuticals financials

Revenue TTM $4.4 million
Gross profit TTM $-1,550,000
Return on assets TTM -36.96%
Return on equity TTM -88.03%
Profit margin 0%
Book value $1.01
Market capitalisation $23 million

TTM: trailing 12 months

Shorting Titan Pharmaceuticals shares

There are currently 403,685 Titan Pharmaceuticals shares held short by investors – that's known as Titan Pharmaceuticals's "short interest". This figure is 4.4% down from 422,416 last month.

There are a few different ways that this level of interest in shorting Titan Pharmaceuticals shares can be evaluated.

Titan Pharmaceuticals's "short interest ratio" (SIR)

Titan Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Titan Pharmaceuticals shares currently shorted divided by the average quantity of Titan Pharmaceuticals shares traded daily (recently around 144689.96415771). Titan Pharmaceuticals's SIR currently stands at 2.79. In other words for every 100,000 Titan Pharmaceuticals shares traded daily on the market, roughly 2790 shares are currently held short.

However Titan Pharmaceuticals's short interest can also be evaluated against the total number of Titan Pharmaceuticals shares, or, against the total number of tradable Titan Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Titan Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Titan Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Titan Pharmaceuticals shares, roughly 48 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Titan Pharmaceuticals.

Find out more about how you can short Titan Pharmaceuticals stock.

Titan Pharmaceuticals share dividends

We're not expecting Titan Pharmaceuticals to pay a dividend over the next 12 months.

Have Titan Pharmaceuticals's shares ever split?

Titan Pharmaceuticals's shares were split on a 1:30 basis on 30 November 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Titan Pharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Titan Pharmaceuticals shares which in turn could have impacted Titan Pharmaceuticals's share price.

Titan Pharmaceuticals share price volatility

Over the last 12 months, Titan Pharmaceuticals's shares have ranged in value from as little as $2.15 up to $9.531. A popular way to gauge a stock's volatility is its "beta".

TTNP.US volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Titan Pharmaceuticals's is 0.7797. This would suggest that Titan Pharmaceuticals's shares are less volatile than average (for this exchange).

Titan Pharmaceuticals overview

Titan Pharmaceuticals, Inc. , a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Titan Pharmaceuticals in the news

There are no recent company news

Frequently asked questions

What percentage of Titan Pharmaceuticals is owned by insiders or institutions?
Currently 6.973% of Titan Pharmaceuticals shares are held by insiders and 17.186% by institutions.
How many people work for Titan Pharmaceuticals?
Latest data suggests 12 work at Titan Pharmaceuticals.
When does the fiscal year end for Titan Pharmaceuticals?
Titan Pharmaceuticals's fiscal year ends in December.
Where is Titan Pharmaceuticals based?
Titan Pharmaceuticals's address is: 400 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
What is Titan Pharmaceuticals's ISIN number?
Titan Pharmaceuticals's international securities identification number is: US8883145075
What is Titan Pharmaceuticals's CUSIP number?
Titan Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 888314101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site